Akebia Therapeutics (AKBA)

$1.41 +0.03 (2.17%)
Market Cap 374.17M
Revenue (ttm) 160.18M
Net Income (ttm) -69.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 6.90
Profit Margin -43.33%
Debt to Equity Ratio 1.15
Volume 2,363,400
Avg Vol 3,008,224
Day's Range N/A - N/A
Shares Out 265.37M
Stochastic %K 33%
Beta 0.35
Analysts Strong Sell
Price Target $5.40

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phospho...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 617 871 2098
Fax: 617 871 2099
Address:
245 First Street, Suite 1400, Cambridge, United States
Justin_Heranus
Justin_Heranus Feb. 4 at 7:54 AM
$AKBA as stated before, the 1.40 zone is crucial. This dickless twats are really trying hard to walk this down... mind you, they broke te 2$ support intentionally, the fckn dicks, that was no coincidence
0 · Reply
Andi77
Andi77 Feb. 4 at 7:18 AM
$AKBA
0 · Reply
john1993
john1993 Feb. 4 at 7:15 AM
$AKBA
0 · Reply
john1993
john1993 Feb. 4 at 7:15 AM
$AKBA
0 · Reply
john1993
john1993 Feb. 4 at 7:14 AM
$AKBA
0 · Reply
john1993
john1993 Feb. 4 at 6:59 AM
$AKBA I really think Blackrock 19m shares and Vanguard 16m shares are lending shares to shorting the stock. That’s the only explanation to what is happening and the shares count make sense with the 37m shares shorts…
0 · Reply
Paperglider
Paperglider Feb. 4 at 5:21 AM
$AKBA seems a good fit! there are probably a couple of other good fits, but who among them have the money or who will value Akebia’s pipeline the most?
0 · Reply
john1993
john1993 Feb. 4 at 4:28 AM
$AKBA that motherfuker john butler did not press release any positive press release for a year now and more. Nothing positive is being shared all bullshit and nothing worthy. John Butler is piece of shi t he only cares about his salary and money. Does not give a flying shi t about any shareholder… like what the FUK. The stock price has been dropping over 8 months now every fuking day red red red and what you see here management diluting more shares in their own pockets instead of putting money and buying from their own money. No they decide to dilute more shares. Fuk you all akebia management and fuk JOHN fuking BUTLER fuking liar piece of SHI T!!!
0 · Reply
john1993
john1993 Feb. 4 at 4:20 AM
$AKBA today’s filling with millions of shares with the $0.00 price show us one thing. They are milking the shit out of this company and we shareholders are nothing to them. Clearly screaming fuk you shareholders we get our shares for free you shareholders buy with your hard earned money and we make you lose value month by month. Like what the hell is this? I swear to god Butler has no shame and that’s insane. Then he go public and say BEST INTEREST OF OUR SHAREHOLDERS” man shut the fuk up you are a piece of sh it manipulator!!
0 · Reply
Paperglider
Paperglider Feb. 4 at 4:05 AM
$AKBA is Akebia the next Chinook? interesting to see Novartis early involvement in Akebia. they still hold 1.3% equity
0 · Reply
Latest News on AKBA
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 2, 2026, 4:05 PM EST - 1 day ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts

Jan 13, 2026, 1:21 PM EST - 21 days ago

Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

Jan 12, 2026, 8:00 AM EST - 22 days ago

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Jan 6, 2026, 8:00 AM EST - 4 weeks ago

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Akebia Announces Establishment of Rare Kidney Disease Pipeline

Dec 1, 2025, 7:00 AM EST - 2 months ago

Akebia Announces Establishment of Rare Kidney Disease Pipeline

Q32 Bio Sells Complement Inhibitor ADX-097

Dec 1, 2025, 7:00 AM EST - 2 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

QTTB

Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 2 months ago

Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 11:01 AM EST - 3 months ago

Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript

Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 10, 2025, 7:00 AM EST - 3 months ago

Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

Nov 6, 2025, 6:30 PM EST - 3 months ago

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

Akebia Therapeutics to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:00 AM EST - 3 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights

Oct 30, 2025, 8:00 AM EDT - 3 months ago

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights

FDA Pushback Prompts Akebia To Drop Broad Label Pursuit For Kidney Disease Drug

Oct 29, 2025, 2:13 PM EDT - 3 months ago

FDA Pushback Prompts Akebia To Drop Broad Label Pursuit For Kidney Disease Drug

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

Oct 28, 2025, 4:30 PM EDT - 3 months ago

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

Oct 20, 2025, 8:08 AM EDT - 3 months ago

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 5, 2025, 1:34 AM EDT - 5 months ago

Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 2, 2025, 4:05 PM EDT - 5 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection

Aug 28, 2025, 8:17 AM EDT - 5 months ago

Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

Aug 21, 2025, 8:00 AM EDT - 5 months ago

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:34 PM EDT - 6 months ago

Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 7, 2025, 7:00 AM EDT - 6 months ago

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference

Aug 6, 2025, 8:00 AM EDT - 6 months ago

Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

Aug 4, 2025, 8:00 AM EDT - 6 months ago

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

Jul 31, 2025, 8:00 AM EDT - 6 months ago

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 8, 2025, 8:00 AM EDT - 7 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

Jun 4, 2025, 8:00 AM EDT - 8 months ago

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:00 AM EDT - 8 months ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

May 27, 2025, 8:00 AM EDT - 9 months ago

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 13, 2025, 8:00 AM EDT - 9 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript

May 8, 2025, 12:44 PM EDT - 9 months ago

Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 7:00 AM EDT - 9 months ago

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

May 1, 2025, 8:00 AM EDT - 9 months ago

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Apr 3, 2025, 8:00 AM EDT - 10 months ago

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Mar 25, 2025, 8:00 AM EDT - 11 months ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Mar 20, 2025, 8:18 AM EDT - 11 months ago

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

MCHP

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Mar 19, 2025, 10:17 PM EDT - 11 months ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Mar 19, 2025, 4:01 PM EDT - 11 months ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 10:21 AM EDT - 11 months ago

Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Mar 13, 2025, 7:00 AM EDT - 11 months ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Mar 6, 2025, 8:00 AM EST - 11 months ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline

Feb 10, 2025, 5:43 AM EST - 1 year ago

Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline

Akebia Therapeutics Announces Multiple Positive Business Updates

Jan 13, 2025, 8:00 AM EST - 1 year ago

Akebia Therapeutics Announces Multiple Positive Business Updates

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Dec 3, 2024, 7:00 AM EST - 1 year ago

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 25, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Q3 2024 Earnings: Hold Akebia Therapeutics

Nov 20, 2024, 3:31 PM EST - 1 year ago

Q3 2024 Earnings: Hold Akebia Therapeutics

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Nov 14, 2024, 8:00 AM EST - 1 year ago

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 12, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 1:59 PM EST - 1 year ago

Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 7, 2024, 7:00 AM EST - 1 year ago

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Justin_Heranus
Justin_Heranus Feb. 4 at 7:54 AM
$AKBA as stated before, the 1.40 zone is crucial. This dickless twats are really trying hard to walk this down... mind you, they broke te 2$ support intentionally, the fckn dicks, that was no coincidence
0 · Reply
Andi77
Andi77 Feb. 4 at 7:18 AM
$AKBA
0 · Reply
john1993
john1993 Feb. 4 at 7:15 AM
$AKBA
0 · Reply
john1993
john1993 Feb. 4 at 7:15 AM
$AKBA
0 · Reply
john1993
john1993 Feb. 4 at 7:14 AM
$AKBA
0 · Reply
john1993
john1993 Feb. 4 at 6:59 AM
$AKBA I really think Blackrock 19m shares and Vanguard 16m shares are lending shares to shorting the stock. That’s the only explanation to what is happening and the shares count make sense with the 37m shares shorts…
0 · Reply
Paperglider
Paperglider Feb. 4 at 5:21 AM
$AKBA seems a good fit! there are probably a couple of other good fits, but who among them have the money or who will value Akebia’s pipeline the most?
0 · Reply
john1993
john1993 Feb. 4 at 4:28 AM
$AKBA that motherfuker john butler did not press release any positive press release for a year now and more. Nothing positive is being shared all bullshit and nothing worthy. John Butler is piece of shi t he only cares about his salary and money. Does not give a flying shi t about any shareholder… like what the FUK. The stock price has been dropping over 8 months now every fuking day red red red and what you see here management diluting more shares in their own pockets instead of putting money and buying from their own money. No they decide to dilute more shares. Fuk you all akebia management and fuk JOHN fuking BUTLER fuking liar piece of SHI T!!!
0 · Reply
john1993
john1993 Feb. 4 at 4:20 AM
$AKBA today’s filling with millions of shares with the $0.00 price show us one thing. They are milking the shit out of this company and we shareholders are nothing to them. Clearly screaming fuk you shareholders we get our shares for free you shareholders buy with your hard earned money and we make you lose value month by month. Like what the hell is this? I swear to god Butler has no shame and that’s insane. Then he go public and say BEST INTEREST OF OUR SHAREHOLDERS” man shut the fuk up you are a piece of sh it manipulator!!
0 · Reply
Paperglider
Paperglider Feb. 4 at 4:05 AM
$AKBA is Akebia the next Chinook? interesting to see Novartis early involvement in Akebia. they still hold 1.3% equity
0 · Reply
Thorthegod
Thorthegod Feb. 4 at 2:10 AM
$AKBA this is insane to give that many shares at once. This would be a multibillion follar Cie i could understand the volume. But here this us totally exagerated.
0 · Reply
Akba_BO
Akba_BO Feb. 4 at 2:09 AM
$AKBA Update severance agreement increasing payout in the event of a change of control followed by new 743,000 RSUs granted to CEO at $0.00 price. 🤔
2 · Reply
Mr_Pithy
Mr_Pithy Feb. 4 at 1:09 AM
$AKBA IT IS GOOD TO BE CEO JOHN P. BUTLER. AN AWARD FOR NEWS WE DON’T KNOW ABOUT YET? GOOD LUCK 🍀 TO US ALL.
2 · Reply
HyacinthCohen
HyacinthCohen Feb. 4 at 12:39 AM
$AKBA Reall??? No ones going talk about all those form 4s that were released after close. Bulter just aquired a ton of shares.
0 · Reply
gaboriar
gaboriar Feb. 4 at 12:20 AM
$AKBA where the fuck are my inducement grants? I’ve worked harder on this last 5 years then those getting the shares.
1 · Reply
MB76
MB76 Feb. 4 at 12:20 AM
$AKBA 37 million shares short! PAY THAT FEE!!!!!!!!!!!!!
0 · Reply
Fashtrades
Fashtrades Feb. 4 at 12:17 AM
$AKBA .. I can promise you one thing if you sold now because of paid bashers such as those clowns 🤡below .. I bet my life that you will regret to sell .. Now
1 · Reply
Hellozz
Hellozz Feb. 3 at 11:36 PM
$AKBA what a boring stock. Hey, sell the damn company $10 per share.
4 · Reply
Chamberlain12
Chamberlain12 Feb. 3 at 11:32 PM
$AKBA DONE
0 · Reply
Chamberlain12
Chamberlain12 Feb. 3 at 11:31 PM
$AKBA I answer. Complete q1 is
0 · Reply
viber7
viber7 Feb. 3 at 11:05 PM
$AKBA Do we know if JB is granting free shares at current prices the way the Fed prints money, or are they options to buy shares at higher prices? If the latter, it is a good incentive to work harder. If the former, not good.
1 · Reply
skagnetti13
skagnetti13 Feb. 3 at 11:03 PM
$AKBA
1 · Reply